12 Oversold Growth Stocks to Buy According to Analysts
On September 27, Wharton professor emeritus and WisdomTree senior economist Jeremy Siegel joined CNBC for an interview to discuss the latest PCE report and what the data reveal about the market.
Vaxcyte Inc. (PCVX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | RA Capital Management Peter Kolchinsky | 11,965,991 | $389,014,367 | -2% | 6.55% |
| 2. | D E Shaw D. E. Shaw | 3,088,450 | $100,405,509 | +256% | 0.07% |
| 3. | Kynam Capital Derrick Tang | 3,071,588 | $99,857,326 | -5% | 10.75% |
| 4. | Deep Track Capital David Kroin | 2,150,000 | $69,896,500 | +187% | 2.24% |
| 5. | Maverick Capital Lee Ainslie | 1,310,605 | $42,607,769 | +9% | 0.64% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $16.00 | 937,500 | $15,000,000.00 | 5,156,553 | 2020-06-16 | Filing | |
| $16.00 | 12,500 | $200,000.00 | 4,168,718 | 2020-06-16 | Filing | |
| $16.00 | 93,000 | $1,488,000.00 | 2,222,967 | 2020-06-16 | Filing | |
| $16.00 | 250,000 | $4,000,000.00 | 2,309,554 | 2020-06-16 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $72.37 | 112 | $8,105.44 | 41,620 | 2025-03-05 | Filing | |
| $71.07 | 2,267 | $161,106.62 | 41,732 | 2025-03-05 | Filing | |
| $70.39 | 2,621 | $184,486.95 | 43,999 | 2025-03-05 | Filing | |
| $73.84 | 2,085 | $153,950.15 | 154,931 | 2025-03-03 | Filing | |
| $73.07 | 5,915 | $432,214.97 | 157,016 | 2025-03-03 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 14,691,344 | $477,656,211 | 0.23% | |
| 2. | 12,151,050 | $395,030,620 | 0.02% | |
| 3. | 11,997,085 | $390,025,233 | 0.01% | |
| 4. | 10,642,243 | $345,979,336 | 0.01% | |
| 5. | 4,954,804 | $161,080,679 | 0.03% |
News See All
12 Best Strong Buy Stocks to Invest in According to Wall Street
On September 26, Peter Boockvar, chief investment officer at One Point BFG Wealth Partners, appeared on CNBC to talk about the likelihood of the Federal Reserve’s interest rate cuts, new inflation data...
TSCM U.S. Small Cap Growth Strategy Exited Vaxcyte (PCVX) as Its Infant Trial was Less Than Compelling
TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” second-quarter 2025 investor letter.
Vaxcyte, Inc. (PCVX)’s VAX-24 Achieves Phase 2 Success in Infants
Vaxcyte, Inc. (NASDAQ:PCVX) is a clinical-stage biotech company focused on developing next-generation pneumococcal conjugate vaccines (PCVs) to prevent invasive pneumococcal disease (IPD).
11 Best Future Stocks to Buy Now
Over the past year, investors have poured money into cutting-edge technologies like artificial intelligence and electric cars.
12 Oversold NASDAQ Stocks to Buy Now
On July 14, Max Kettner, chief multi-asset strategist at HSBC, appeared on CNBC to talk about the global markets amid trade tensions.
Here’s Why Vaxcyte (PCVX) Sold Off in Q1
PGIM Jennison Health Sciences Fund released its first quarter 2025 investor letter. A copy of the letter can be downloaded here.
Cantor Fitzgerald Maintains Overweight on Vaxcyte Amid Vaccine Development and ACIP Meeting
Vaxcyte Inc. (NASDAQ:PCVX) ranks among the 30 stocks expected to beat the market by 20 percentage points this year. On June 10, Cantor Fitzgerald reiterated its Overweight rating for Vaxcyte Inc.
30 Stocks Expected To Beat the Market By 20 Percentage Points This Year
The US stock market has gone through a turbulent journey this year. Following a correction in March and a lull in April, the S&P 500 recovered its losses in May and June.
Here’s Why Vaxcyte (PCVX) Sold Off in Q1
Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Small Cap Growth Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here.